Study of NNZ-2566 in Patients With Traumatic Brain Injury

PHASE2CompletedINTERVENTIONAL
Enrollment

261

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Brain Injuries
Interventions
DRUG

NNZ-2566

"Solution for intravenous infusion.~20 mg/kg intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion of 1, 3, or 6 mg/kg/h for a total of 72 consecutive hours."

DRUG

Placebo

Sodium Chloride 0.9% Injection

Trial Locations (20)

13210

SUNY Upstate Medical University, Syracuse

15213

University of Pittsburgh Medical Center, Pittsburgh

18015

St Luke's University Hospital, Bethlehem

22042

Inova Fairfax Hospital, Falls Church

25304

Charleston Area Medical Center, Charleston

33136

University of Miami, Lois Pope Life Center, Miami

36617

University of South Alabama, Mobile

45219

University of Cincinnati, Mayfield Clinic, Cincinnati

45409

Miami Valley Hospital, Dayton

48201

Detroit Receiving Hospital and University Health Center, Detroit

48235

Sinai Grace Hospital, Detroit

49007

Bronson Methodist Hospital, Kalamazoo

53226

University of Wisconsin, Froedtert Hospital, Milwaukee

70808

Our Lady of the Lake Hospital, Baton Rouge

76104

Texas Health Harris Methodist Hospital Fort Worth, Fort Worth

85724

University of Arizona, Tucson

90095

Ronald Reagan UCLA Medical Center, Los Angeles

92324

Arrowhead Regional Medical Center, Colton

95817

University of California, Davis Medical Center, Sacramento

96813

The Queen's Medical Center, Honolulu

Sponsors
All Listed Sponsors
lead

Neuren Pharmaceuticals Limited

INDUSTRY

NCT00805818 - Study of NNZ-2566 in Patients With Traumatic Brain Injury | Biotech Hunter | Biotech Hunter